[Form 4] Aura Biosciences, Inc. Insider Trading Activity
Rhea-AI Filing Summary
Aura Biosciences insider filing reports option exercises and a partial sale to cover costs. On 08/18/2025 Senior Vice President, Finance Amy Elazzouzi exercised long-held options to purchase 12,899 shares of Aura common stock across multiple option tranches and exercise prices. Of those shares, 7,722 were sold in multiple transactions at prices ranging from $6.57 to $6.80 (weighted average reported as $6.70). Following the transactions the reporting person beneficially owns 86,558 shares and holds no remaining derivative securities from the exercised options. The filing states the specific exercise prices and vesting/exercise dates for each option tranche.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine option exercise with partial sell-to-cover; limited market impact but increases insider equity stake.
The filing documents the exercise of 12,899 option shares by a senior finance officer, with 7,722 shares sold at prices between $6.57 and $6.80 to cover costs. The net result is a reported beneficial ownership of 86,558 shares. This is a common administration of long-held, vested options rather than an unexpected liquidity event. The granular exercise prices and expiration dates are disclosed, and all options reported as exercised were long-held and many are fully vested as noted.
TL;DR: Disclosure is compliant and transparent; transactions appear consistent with typical executive option exercises.
The Form 4 provides required detail: transaction codes, exercise prices, number of shares acquired and sold, and post-transaction beneficial ownership. The seller provided a weighted average sale price and committed to furnish per-price breakdown on request, which supports transparency. No derivative holdings remain from these exercised options according to the filing, and the signature certifies the report.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 2,554 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 1,094 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 547 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 547 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 4,744 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 1,094 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 2,319 | $0.00 | -- |
| Exercise | Common Stock | 2,554 | $5.07 | $13K |
| Exercise | Common Stock | 1,094 | $5.48 | $6K |
| Exercise | Common Stock | 547 | $5.48 | $3K |
| Exercise | Common Stock | 547 | $5.21 | $3K |
| Exercise | Common Stock | 4,744 | $2.74 | $13K |
| Exercise | Common Stock | 1,094 | $3.16 | $3K |
| Exercise | Common Stock | 2,319 | $4.25 | $10K |
| Sale | Common Stock | 7,722 | $6.70 | $52K |
Footnotes (1)
- On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.57 to $6.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This option is fully vested.
